Human papilloma virus

Where the papers sit

26 papers from the last 6 months study human papilloma virus directly · updated from PubMed 6 Oct 2026

• HPV Vaccination Uptake and Policy

  HPV vaccination is shifting from guideline design toward broader, more equitable delivery and measurable population benefit. Studies repeatedly examine uptake barriers involving childhood adversity, age of sexual debut, consent laws and access for unvaccinated students. Policy models quantify return on investment, while real-world data test protection against high-risk HPV DNA in adult women. A few studies extend the topic to HPV-related cancer biomarkers and candidate antiviral compounds.

  9 papers · 34.6%

• Vaccine Uptake and Formulation

  Vaccine programs are being treated as both an access problem and a product-design problem. HPV uptake studies focus on hesitancy, social-media effects, migrant and LGBTQIA+ access, and non-uptake among adolescent girls. Parallel formulation work seeks stronger potency through mRNA lipid nanoparticles and chitosan-based assays. The cluster supports integrated delivery and manufacturing improvements, but it does not establish one dominant intervention.

  8 papers · 30.8%

• HPV Vaccination and Cancer Prevention

  HPV vaccination is framed as a cancer-prevention investment, with modeling used to compare costs and population benefit. The quadrivalent vaccine targeting types 6, 11, 16 and 18 remains central, alongside screening and broader prevention strategies. Knowledge and willingness among young women recur as practical determinants of coverage. The evidence points toward pairing vaccination with education and screening rather than relying on any single measure.

  3 papers · 11.5%

• Others — HPV Monitoring and Prevention

  Cervical cancer work pairs post-treatment HPV detection with recurrence assessment, while prevention research targets vaccination acceptance and L2-based immunity. AAV2-like particles are being explored as alternative immunogens, and wastewater metagenomics extends surveillance beyond clinics. Findings also question the reliability of tumor microbiota signals across contexts. The topics share HPV monitoring and prevention but do not form a single research direction.

  6 papers · 23.1%